

S3 Table. Baseline characteristics of patients with or without pre-RT sarcopenia after propensity score-matching

Characteristic	Non-sarcopenia (n=47)	Sarcopenia (n=47)	p-value
Age (yr), median (range)	67 (34-84)	70 (35-92)	0.256
Sex			0.748
Male	42 (89.4)	41 (87.2)	
Female	5 (10.6)	6 (12.8)	
Performance status (ECOG)			0.797
0	10 (21.3)	9 (19.1)	
≥1	37 (78.7)	38 (80.9)	
Body mass index (kg/m ²), median (range)	23.7 (18.6-30.9)	23.6 (18.2-30.5)	0.978
Smoking			0.309
Never	20 (42.6)	18 (38.3)	
Former	7 (14.9)	13 (27.7)	
Active	20 (42.6)	16 (34.0)	
Pathology			0.538
Adenocarcinoma	20 (42.6)	15(31.9)	
Squamous cell carcinoma	26 (55.3)	30 (63.8)	
Others	1 (2.1)	2 (4.3)	
T category (AJCC 8th edition)			0.118
T1	7 (14.9)	1 (2.1)	
T2	10 (21.3)	15 (31.9)	
T3	12 (25.5)	15 (31.9)	
T4	18 (38.3)	16 (34.0)	
N category (AJCC 8th edition)			0.940
N0	4 (8.5)	4 (8.5)	
N1	4 (8.5)	6 (12.8)	
N2	19 (40.4)	17 (36.2)	
N3	20 (42.6)	20 (42.6)	
Overall stage (AJCC 8th edition)			0.913
IIIA	17 (36.2)	16 (34.0)	
IIIB	17 (36.2)	19 (40.4)	
IIIC	13 (27.7)	12 (25.5)	
PD-L1 expression level (%)			0.342
≥25	23 (48.9)	27 (57.4)	
1-24	21 (44.7)	15 (31.9)	
<1	1 (2.1)	1 (2.1)	
Unknown	2 (4.3)	4 (8.5)	
EGFR mutation status			0.303
Positive	1 (2.1)	4 (8.5)	
Negative	35 (74.5)	29 (61.7)	
Unknown	11 (23.4)	14 (29.8)	
ALK mutation status			0.351
Positive	0	3 (6.4)	
Negative	25 (53.2)	23 (48.9)	
Unknown	22 (46.8)	21 (44.7)	
Concurrent chemotherapy regimen			> 0.99
Paclitaxel and carboplatin	47 (100)	46 (97.9)	
Cisplatin	0	1 (2.1)	
PTV volume (cm ³), median (range)	432.8 (85.1-1,572.6)	482.1 (205.1-1,022.8)	0.452
Mean lung dose (Gy), median (range)	12.9 (5.2-22.0)	13.5 (7.0-22.4)	0.261

Mean heart dose (Gy), median (range)	10.2 (0.7-29.9)	9.2 (0.9-25.4)	0.545
Baseline ALC ($\times 10^3$ cells/ μ L), mean (range)	2.01 \pm 0.50 (0.95-3.01)	1.90 \pm 0.62 (0.70-3.64)	0.384

Values are presented as number (%) unless otherwise indicated. AJCC, American Joint Committee on Cancer; ALC, absolute lymphocyte count; ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitor; PD-L1, programmed death ligand-1; RT, radiotherapy; PTV, planning target volume.